170.85

0.89% 1.4533

Becton Dickinson Co (BDX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BDX? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$169.40

Offen:

$168.72

24-Stunden-Volumen:

790.70K

Relative Volume:

0.29

Marktkapitalisierung:

$48.97B

Einnahmen:

$20.87B

Nettoeinkommen (Verlust:

$1.50B

KGV:

32.61

EPS:

5.24

Netto-Cashflow:

$2.59B

1W Leistung:

-2.06%

1M Leistung:

+1.26%

6M Leistung:

-22.76%

1J Leistung:

-28.44%

1-Tages-Spanne:

$167.94

$171.38

1-Wochen-Bereich:

$167.94

$176.43

52-Wochen-Spanne:

$163.33

$251.99

Becton Dickinson Co Stock (BDX) Company Profile

Firmenname

Becton Dickinson Co

Sektor

Healthcare (1170)

Branche

Medical Instruments & Supplies (64)

Telefon

(201) 847-6800

Adresse

ONE BECTON DR, FRANKLIN LAKES

Mitarbeiter

74,000

Twitter

@BDandCo

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

BDX's Discussions on Twitter

Vergleichen Sie BDX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BDX Becton Dickinson Co	170.87	50.02B	20.87B	1.50B	2.59B	5.24
ISRG Intuitive Surgical Inc	550.41	197.20B	8.71B	2.48B	1.75B	6.82
ALC Alcon Inc	85.16	42.88B	9.93B	1.12B	1.58B	2.25
RMD Resmed Inc	246.50	36.10B	5.02B	1.31B	1.56B	8.91
BAX Baxter International Inc	29.93	15.84B	11.89B	-560.00M	191.00M	-1.10

Becton Dickinson Co Stock (BDX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-22	Herabstufung	Citigroup	Buy → Neutral
2025-05-02	Herabstufung	Goldman	Buy → Neutral
2025-05-02	Herabstufung	Piper Sandler	Overweight → Neutral
2025-05-02	Herabstufung	Raymond James	Outperform → Mkt Perform
2025-05-01	Herabstufung	BofA Securities	Buy → Neutral
2025-05-01	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-05-01	Herabstufung	William Blair	Outperform → Mkt Perform
2024-10-01	Hochstufung	Citigroup	Neutral → Buy
2024-05-30	Eingeleitet	Goldman	Buy
2023-07-24	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-05-30	Fortgesetzt	Morgan Stanley	Overweight
2023-05-05	Hochstufung	Piper Sandler	Neutral → Overweight
2023-04-12	Hochstufung	KeyBanc Capital Markets	Sector Weight → Overweight
2023-01-03	Hochstufung	BofA Securities	Neutral → Buy
2022-12-12	Hochstufung	Citigroup	Sell → Neutral
2022-07-11	Herabstufung	Citigroup	Neutral → Sell
2022-06-24	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-03-18	Fortgesetzt	Raymond James	Mkt Perform
2022-03-02	Fortgesetzt	BofA Securities	Neutral
2021-12-08	Herabstufung	Piper Sandler	Overweight → Neutral
2021-08-06	Herabstufung	JP Morgan	Overweight → Neutral
2021-05-25	Eingeleitet	Barclays	Equal Weight
2020-12-15	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-12-15	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-07-09	Hochstufung	Barclays	Equal Weight → Overweight
2020-06-01	Fortgesetzt	Goldman	Buy
2020-03-05	Eingeleitet	Citigroup	Neutral
2020-02-07	Herabstufung	Cowen	Outperform → Market Perform
2020-02-07	Herabstufung	KeyBanc Capital Markets	Overweight → Sector Weight
2020-02-07	Herabstufung	Raymond James	Strong Buy → Outperform
2020-02-06	Herabstufung	Cowen	Outperform → Market Perform
2020-01-08	Herabstufung	Barclays	Overweight → Equal Weight
2019-05-13	Hochstufung	Barclays	Equal Weight → Overweight
2018-12-07	Eingeleitet	Deutsche Bank	Buy
2018-10-16	Eingeleitet	Barclays	Equal Weight
2018-06-21	Hochstufung	JP Morgan	Neutral → Overweight
2018-04-10	Hochstufung	Citigroup	Neutral → Buy
2018-01-19	Fortgesetzt	BofA/Merrill	Buy
2018-01-05	Hochstufung	Citigroup	Sell → Neutral
2018-01-05	Eingeleitet	KeyBanc Capital Mkts	Overweight
2018-01-03	Eingeleitet	Evercore ISI	Outperform
2017-12-29	Bestätigt	Deutsche Bank	Buy

Alle ansehen

Becton Dickinson Co Aktie (BDX) Neueste Nachrichten

09:18 AM

Becton Dickinson (BDX) Maintains Overweight Rating Despite Price Target Cut | BDX Stock News - GuruFocus

09:18 AM

07:44 AM

Barclays Adjusts Price Target on Becton, Dickinson and Company to $241 From $261 - marketscreener.com

07:44 AM

07:06 AM

Barclays lowers Becton Dickinson stock price target to $241 - Investing.com

07:06 AM

06:56 AM

Becton Dickinson and : BD Vascular Access Management Recognized with Seal of Approval from Infusion Nurses Society - marketscreener.com

06:56 AM

06:47 AM

Becton Dickinson (BDX) Receives Adjusted Price Target from Barclays | BDX Stock News - GuruFocus

06:47 AM

Jun 02, 2025

Insider Sell: David Shan Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus

Jun 02, 2025

May 29, 2025

Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.

May 29, 2025

May 28, 2025

Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance

May 28, 2025

Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex?? Atherectomy System in Treatment of Peripheral Artery Disease - marketscreener.com

May 28, 2025

BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - BD Newsroom

May 28, 2025

BD's Groundbreaking 600-Patient Registry to Transform PAD Treatment Data: First Major US Study - Stock Titan

May 28, 2025

May 27, 2025

Becton Dickinson’s SWOT analysis: stock’s future hangs on life sciences spin-off - Investing.com

May 27, 2025

Saudi Arabia Research Antibodies Market Report 2025-2030, - GlobeNewswire

May 27, 2025

Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck - Yahoo Finance

May 27, 2025

May 25, 2025

AC Health, Becton Dickinson team up to elevate healthcare standards across Asia - Bilyonaryo Business News

May 25, 2025

May 22, 2025

Becton Dickinson stock rating cut by Citi to Neutral, target to $185 - Investing.com India

May 22, 2025